Family Capital Management Inc. Invests $400,000 in Astrazeneca Plc $AZN

Family Capital Management Inc. acquired a new position in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 4,350 shares of the company’s stock, valued at approximately $400,000.

Several other large investors have also recently modified their holdings of the stock. Binnacle Investments Inc increased its holdings in shares of Astrazeneca by 21.8% in the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after buying an additional 118 shares during the period. 44 Wealth Management LLC increased its holdings in shares of Astrazeneca by 0.7% in the third quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock worth $1,283,000 after buying an additional 124 shares during the period. CoreCap Advisors LLC increased its holdings in shares of Astrazeneca by 30.6% in the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after buying an additional 125 shares during the period. Highline Wealth Partners LLC increased its holdings in shares of Astrazeneca by 32.0% in the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after buying an additional 129 shares during the period. Finally, Traub Capital Management LLC increased its holdings in shares of Astrazeneca by 3.3% in the third quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock worth $316,000 after buying an additional 130 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Shares of Astrazeneca stock opened at $200.86 on Tuesday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The company has a market cap of $311.51 billion, a P/E ratio of 34.60, a price-to-earnings-growth ratio of 1.54 and a beta of 0.35. Astrazeneca Plc has a 52 week low of $132.32 and a 52 week high of $212.71.

Astrazeneca Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s payout ratio is presently 74.83%.

Analyst Ratings Changes

AZN has been the topic of several analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Citigroup assumed coverage on shares of Astrazeneca in a research report on Tuesday, January 27th. They issued a “buy” rating on the stock. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Finally, Weiss Ratings initiated coverage on Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and an average target price of $102.67.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.